What Is Blood Therapy for Cancer
Blood therapy for cancer includes treatments that use components of blood, such as immune cells, antibodies, and plasma-derived factors, to target tumors. CAR-T cell therapy, checkpoint inhibitors, and bispecific antibodies are leading examples of blood-derived approaches that modify or harness the immune system. These therapies are administered intravenously and rely on precise biological targeting rather than traditional chemotherapy or radiation.
Regulatory agencies such as the FDA have approved multiple blood-based cancer therapies across hematologic and select solid tumor indications. CAR-T products like tisagenlecleucel and axicabtagene ciloleucel have transformed treatment pathways for certain lymphomas and leukemias. Companies including Novartis, Kite Pharma, and Bristol-Myers Squibb have commercialized these therapies, with ongoing expansion into earlier lines of treatment.
Leading Companies and Approved Products
Novartis, Kite Pharma, Bristol-Myers Squibb, and Johnson & Johnson are among the top firms developing and commercializing blood-based cancer therapies. Kite Pharma, acquired by Gilead Sciences, markets Yescarta for large B-cell lymphoma, while Novartis offers Kymriah for B-cell acute lymphoblastic leukemia. These products represent a significant share of the cell therapy market and are included in treatment guidelines by organizations such as the National Comprehensive Cancer Network.
Bristol-Myers Squibb's Opdivo and Merck's Keytruda are checkpoint inhibitors that modulate immune responses and are administered via intravenous infusion. These drugs have achieved blockbuster revenues, with combined annual sales exceeding 20 billion dollars in recent fiscal years. Companies continue to invest in next-generation blood therapies, including engineered cell products and bispecific antibodies, to address unmet needs in oncology.
Clinical Data, Market Trends, and Safety Considerations
Clinical trials have shown that CAR-T therapies can achieve high response rates in relapsed or refractory blood cancers, with complete remission rates ranging from 50 to 80 percent depending on the product and patient population. However, these treatments carry risks such as cytokine release syndrome and neurotoxicity, requiring specialized monitoring and supportive care. Real-world data from registries and post-market surveillance continue to refine safety profiles and treatment protocols.
The global cell therapy market is projected to grow significantly as new approvals expand and manufacturing processes become more efficient. Companies are investing in automated production platforms and allogeneic off-the-shelf products to improve access and reduce costs. Investors track these developments closely, with funding rounds and partnerships often reported by financial outlets such as Forbes and regulatory updates shared through official channels like the SEC.